By Paige Minemyer
CVS Health is planning to double the number of its drive-thru testing sites by mid-October, the healthcare giant announced on Thursday.
read more
By Ben Adams
Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Despite some forward motion over the summer, studies for new drugs are still suffering.
read more
By Kyle Blankenship
Months of fervid research have whittled away most potential options to treat patients with COVID-19, but group of antibody cocktails remain promising. And Eli Lilly believes so strongly in its contender, partnered with the biotech AbCellera, that it's bringing on a major pharma partner to chip in on production.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner
After Moderna unveiled its vaccine's phase 3 trial protocol, Pfizer followed suit Thursday afternoon. Plus, a group of state treasurers asked Gilead to reconsider its price for remdesivir.
read more
By Conor Hale
Diagnostic maker Cellex has announced plans to develop a rapid coronavirus infection test that people can fully perform at home, from sample collection to result—with 15-minute readings double-checked by a personal smartphone app.
read more
By Angus Liu
BioNTech and its partner Pfizer have multiple COVID-19 vaccine supply deals in the bag, and a major expansion of production is due. The German biotech has agreed to buy a biologics facility in its home country from Novartis, hoping to boost its annual capacity by up to 750 million doses.
read more
By Heather Landi
Employers recognize there is a looming behavioral health crisis stemming from the pandemic and that's driving demand for mental health tools for employees. Health benefits platform Accolade is teaming up with Ginger to provide a health benefits solution that integrates physical and mental healthcare for employees.
read more
By Beth Snyder Bulik
Vaccine marketing messages are flooding media channels this fall. Pharma companies, industry groups and even the federal government are putting out information about vaccine availability and safety, and Pfizer is set to be the latest to join them.
read more
By Kyle Blankenship
Eastman Kodak's pharma ambitions took a hit when insider trading accusations put $765 million in U.S. funding on the skids. But a special committee hired by Kodak's board has now cleared its top brass of wrongdoing—a decision that could clear its path into drug manufacturing.
read more
